Finance PhD: Move Your Money Before April 30th
The clock just starting ticking on the biggest financial event in 20 years. The next few weeks could decide your wealth in 2021.
See what you should do now

INZY Insider Trading (Inozyme Pharma)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $13,000,000.00
Insider Selling (Last 12 Months): $7,875,000.00

Inozyme Pharma Insider Trading History Chart

Inozyme Pharma Share Price & Price History

$19.02
▼ -0.26 (-1.35%)
As of 04/9/2021 01:00 AM ET
Days: 30 | 90 | 365
Get out of cash NOW
Millionaire Wall Street Legend Urges Americans To Get Out Of CASH before April 27th.
Details here.
pixel

Inozyme Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/28/2021Holdings A/S NovoMajor ShareholderSell375,000$21.00$7,875,000.002,194,379  
7/28/2020Longitude Capital Partners IiiMajor ShareholderBuy625,000$16.00$10,000,000.00
7/28/2020Robert Lorne HopfnerDirectorBuy187,500$16.00$3,000,000.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Inozyme Pharma (NASDAQ:INZY)

69.77% of Inozyme Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Inozyme Pharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
3/12/2021DekaBank Deutsche Girozentrale7,000$0.17M0.0%N/A0.030%
2/19/2021JPMorgan Chase & Co.3,836$79K0.0%+26.6%0.016%
2/16/2021Baker BROS. Advisors LP106,999$2.21M0.0%-9.7%0.458%
2/16/2021Nuveen Asset Management LLC21,292$0.44M0.0%+24.7%0.091%
2/16/2021Avidity Partners Management LP9,683$0.20M0.0%-84.3%0.041%
2/16/2021Charles Schwab Investment Management Inc.49,045$1.01M0.0%+1.5%0.210%
2/12/2021CHI Advisors LLC995,396$20.55M5.8%-1.4%4.259%
2/11/2021Citigroup Inc.2,236$46K0.0%+473.3%0.010%
2/9/2021Wells Fargo & Company MN9,696$0.20M0.0%+58.6%0.041%
2/9/2021Pivotal bioVenture Partners Investment Advisor LLC1,591,154$32.84M10.8%N/A6.808%
2/9/2021Bank of New York Mellon Corp21,349$0.44M0.0%+10.1%0.091%
2/8/2021New York State Common Retirement Fund7,400$0.15M0.0%N/A0.032%
2/5/2021BlackRock Inc.630,751$13.02M0.0%+25.9%2.699%
2/4/2021State of Wisconsin Investment Board11,400$0.24M0.0%N/A0.049%
12/30/2020Deerfield Management Company L.P. Series C1,150,299$30.24M0.6%N/A4.921%
12/14/2020Strs Ohio2,000$52K0.0%N/A0.009%
11/17/2020California State Teachers Retirement System12,298$0.32M0.0%N/A0.053%
11/16/2020State of Tennessee Treasury Department9,044$0.24M0.0%N/A0.039%
11/13/2020Morgan Stanley1,251$33K0.0%N/A0.005%
11/13/2020Charles Schwab Investment Management Inc.48,334$1.27M0.0%N/A0.207%
11/13/2020Sofinnova Investments Inc.2,028,308$53.32M4.0%N/A8.681%
11/12/2020JPMorgan Chase & Co.3,029$72K0.0%N/A0.013%
11/12/2020Yale University113,502$2.98M9.1%N/A0.486%
11/12/2020Sphera Funds Management LTD.196,411$5.16M0.5%N/A0.841%
11/10/2020State Street Corp70,585$1.86M0.0%N/A0.302%
11/6/2020NEA Management Company LLC2,444,379$64.26M2.7%N/A10.462%
11/6/2020BlackRock Inc.500,934$13.17M0.0%N/A2.144%
11/5/2020California Public Employees Retirement System16,011$0.42M0.0%N/A0.069%
Data available starting January 2016

See Full Table
Inozyme Pharma logo
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $19.02
$18.74
$19.37

50 Day Range

MA: $20.28
$17.77
$22.14

52 Week Range

Now: $19.02
$16.10
$31.65

Volume

16,195 shs

Average Volume

63,536 shs

Market Capitalization

$446.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Inozyme Pharma?

Inozyme Pharma's top insider investors include:
  1. Holdings A/S Novo (Major Shareholder)
  2. Longitude Capital Partners Iii (Major Shareholder)
  3. Robert Lorne Hopfner (Director)
Finance PhD: Move Your Money Before April 30th
The clock just starting ticking on the biggest financial event in 20 years. The next few weeks could decide your wealth in 2021.
See what you should do now